BARDA Funding Development of First Marburg Vaccine

The Marburg virus is part of the family of hemorrhagic fever viruses that includes Ebola. The virus causes a similar illness to that of Ebola and occurs most often in Africa. The Marburg virus was recognized in 1967 and, since then, multiple outbreaks have occurred with high mortality rates, most recently in 2017.

Moving to increase national health security against biothreats and protect public health, the U.S. Department of Health and Human Services announced it will partner with Public Health Vaccines LLC of Cambridge, Mass., to develop a potential vaccine against Marburg virus. No licensed vaccine for this virus exists at this time, HHS reported.

The Marburg virus is part of the family of hemorrhagic fever viruses that includes Ebola. The virus causes a similar illness to that of Ebola and occurs most often in Africa. The Marburg virus was recognized in 1967 and, since then, multiple outbreaks have occurred with high mortality rates, most recently in 2017. The Marburg virus, like Ebola, is deemed a potential bioterrorism threat by the U.S. Department of Homeland Security.

BARDA, the Biomedical Advanced Research and Development Authority that is part of the HHS Office of the Assistant Secretary for Preparedness and Response, awarded an initial two-year, $10 million contract to Public Health Vaccines LLC to begin development of a vaccine. "This vaccine candidate is the first BARDA has funded against the Marburg virus, and it is an important step toward meeting an urgent public health and biodefense need," said BARDA Director Rick Bright, Ph.D. "We will leverage our experience in establishing public-private partnerships that bring results that are critical to saving lives and protecting Americans – and possibly people across the globe – from health security threats."

The Public Health Agency of Canada initially developed the vaccine and licensed it to Public Health Vaccines LLC. This approach is similar to the one Merck & Co. used to develop its Ebola vaccine. Under the agreement with BARDA, Public Health Vaccines LLC will conduct preclinical development to demonstrate the proof of concept that the vaccine can protect against Marburg virus. If the initial development succeeds, BARDA has the option to provide additional funding for a total of up to $72 million to advance the Marburg virus vaccine through a Phase 2 clinical trial and begin development of a vaccine candidate against the Sudan ebolavirus, a closely related virus, as well.

Download Center

  • Safety Metrics Guide

    Is your company leveraging its safety data and analytics to maintain a safe workplace? With so much data available, where do you start? This downloadable guide will give you insight on helpful key performance indicators (KPIs) you should track for your safety program.

  • Job Hazard Analysis Guide

    This guide includes details on how to conduct a thorough Job Hazard Analysis, and it's based directly on an OSHA publication for conducting JHAs. Learn how to identify potential hazards associated with each task of a job and set controls to mitigate hazard risks.

  • A Guide to Practicing “New Safety”

    Learn from safety professionals from around the world as they share their perspectives on various “new views” of safety, including Safety Differently, Safety-II, No Safety, Human and Organizational Performance (HOP), Resilience Engineering, and more in this helpful guide.

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • EHS Software Buyer's Guide

    Learn the keys to staying organized, staying sharp, and staying one step ahead on all things safety. This buyer’s guide is designed for you to use in your search for the safety management solution that best suits your company’s needs.

  • Vector Solutions

OH&S Digital Edition

  • OHS Magazine Digital Edition - June 2022

    June 2022

    Featuring:

    • SAFETY CULTURE
      Corporate Safety Culture Is Workplace Culture
    • HEAT STRESS
      Keeping Workers Safe from Heat-Related Illnesses & Injuries
    • EMPLOYEE HEALTH SCREENING
      Should Employers Consider Oral Fluid Drug Testing?
    • PPE FOR WOMEN
      Addressing Physical Differences
    View This Issue